Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Free Cash Flow (2016 - 2025)

Haemonetics (HAE) has 17 years of Free Cash Flow data on record, last reported at $87.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 147.63% year-over-year to $87.2 million; the TTM value through Dec 2025 reached $308.1 million, up 211.41%, while the annual FY2025 figure was $142.4 million, 0.82% down from the prior year.
  • Free Cash Flow reached $87.2 million in Q4 2025 per HAE's latest filing, down from $106.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $106.3 million in Q3 2025 and bottomed at -$33.1 million in Q2 2024.
  • Average Free Cash Flow over 5 years is $32.0 million, with a median of $34.1 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: crashed 478.98% in 2021, then surged 526.93% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $22.6 million in 2021, then soared by 110.03% to $47.6 million in 2022, then plummeted by 131.93% to -$15.2 million in 2023, then soared by 331.92% to $35.2 million in 2024, then soared by 147.63% to $87.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $87.2 million in Q4 2025, $106.3 million in Q3 2025, and $13.6 million in Q2 2025.